BLC
INO icon

Brown, Lisle/Cummings’s Inovio Pharmaceuticals INO Stock Holding History

Brown, Lisle/Cummings’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed -$4 – 567
2023
Q4 		$4 Hold
1
– – ﹤0.01% 570
2023
Q3 		$3 Hold
1
– – ﹤0.01% 549
2023
Q2 		$3 Hold
1
– – ﹤0.01% 555
2023
Q1 		$6 Hold
1
– – ﹤0.01% 532
2022
Q4 		$11 Hold
1
– – ﹤0.01% 520
2022
Q3 		$12 Hold
1
– – ﹤0.01% 511
2022
Q2 		$12 Buy
+1
New +$28 ﹤0.01% 475

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Brown, Lisle/Cummings's INO Position: Q1 2024 in Review

Brown, Lisle/Cummings sold out of Inovio Pharmaceuticals (INO) in Q1 2024, closing a stake of 1 share — an estimated $4 sold.

Brown, Lisle/Cummings first reported a position in INO in Q2 2022 and held it in 7 quarters. The position peaked at $12 in Q3 2022. 89 funds tracked by Wall St. Rank hold INO as of Q1 2024.

  • Brown, Lisle/Cummings reported no remaining Inovio Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Brown, Lisle/Cummings sold 1 Inovio Pharmaceuticals share in Q1 2024, an estimated $4.
  • Brown, Lisle/Cummings first reported a position in Inovio Pharmaceuticals in Q2 2022 and held it in 7 quarters.
  • Brown, Lisle/Cummings's Inovio Pharmaceuticals position peaked at $12 in Q3 2022.
  • 89 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2024.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2024, filed 1 Jul 2024.